9.37

1.37% -0.13

Avadel Pharmaceuticals Plc (AVDL)

Overview News Price History Option Chain Financials Why AVDL Down? Discussions Forecast

Avadel Pharmaceuticals Plc stock is traded at $9.37, with a volume of 1.71M. It is down -1.37% in the last 24 hours and up +4.00% over the past month. Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Previous Close:

$9.50

Open:

$9.52

24h Volume:

1.71M

Relative Volume:

1.47

Market Cap:

$989.64M

Revenue:

$47.56M

Net Income/Loss:

$-156.83M

P/E Ratio:

-5.1202

EPS:

-1.83

Net Cash Flow:

$-127.98M

1W Performance:

-8.41%

1M Performance:

+4.00%

6M Performance:

-12.67%

1Y Performance:

-40.28%

1-Day Range:

$9.28

$9.76

1-Week Range:

$9.10

$10.35

52-Week Range:

$6.38

$17.30

Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile

Name

Avadel Pharmaceuticals Plc

Sector

Healthcare (1172)

Industry

Drug Manufacturers - Specialty & Generic (82)

Phone

636-449-1830

Address

BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN

Employee

188

Twitter

@AvadelPharma

Next Earnings Date

2025-03-03

Latest SEC Filings

AVDL's Discussions on Twitter

Compare AVDL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVDL Avadel Pharmaceuticals Plc	9.37	989.64M	47.56M	-156.83M	-127.98M	-1.83
RGC Regencell Bioscience Holdings Ltd	78.00	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	161.67	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.50	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.89	47.60B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.89	20.17B	16.54B	-1.64B	749.00M	-1.45

Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Buy
Jun-12-24	Initiated	Rodman & Renshaw	Buy
Mar-05-24	Reiterated	H.C. Wainwright	Buy
Mar-05-24	Reiterated	Needham	Buy
Mar-05-24	Reiterated	Oppenheimer	Outperform
Feb-06-24	Initiated	UBS	Buy
Nov-30-22	Upgrade	Jefferies	Hold → Buy
Aug-10-22	Downgrade	Jefferies	Buy → Hold
Jul-28-22	Resumed	Craig Hallum	Buy
May-26-22	Downgrade	Stifel	Buy → Hold
Sep-23-21	Initiated	Needham	Buy
Jul-31-20	Initiated	Oppenheimer	Outperform
Jul-21-20	Initiated	SVB Leerink	Outperform
Jun-30-20	Initiated	H.C. Wainwright	Buy
Apr-03-20	Initiated	Jefferies	Buy
Mar-12-20	Initiated	Stifel	Buy
Feb-26-20	Initiated	Piper Sandler	Overweight
Jan-30-20	Initiated	Craig Hallum	Buy
Jun-14-19	Upgrade	Ladenburg Thalmann	Neutral → Buy
Feb-08-19	Downgrade	Ladenburg Thalmann	Buy → Neutral

View All

Avadel Pharmaceuticals Plc Stock (AVDL) Latest News

Jun 16, 2025

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 16, 2025

Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High? - Yahoo Finance

Jun 16, 2025

Jun 13, 2025

Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock - Yahoo Finance

Jun 13, 2025

AVDL Stock Update: Avadel Pharmaceuticals plc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com

Jun 13, 2025

Jun 11, 2025

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Purchased by California State Teachers Retirement System - Defense World

Jun 11, 2025

Jun 10, 2025

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way? - simplywall.st

Jun 10, 2025

Following a 34% decline over last year, recent gains may please Avadel Pharmaceuticals plc (NASDAQ:AVDL) institutional owners - Yahoo Finance

Jun 10, 2025

Jun 09, 2025

Bank of America Corp DE Decreases Position in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World

Jun 08, 2025

Jun 07, 2025

Avadel gets FDA's Orphan Drug status for sleep disorder treatment - MSN

Jun 07, 2025

Jun 05, 2025

FDA grants orphan drug status to Avadel’s IH treatment By Investing.com - Investing.com South Africa

Jun 05, 2025

Avadel Pharmaceuticals (AVDL) Secures FDA Orphan Drug Status - GuruFocus

Jun 05, 2025

Avadel Pharmaceuticals at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK

Jun 05, 2025

Avadel Pharmaceuticals (AVDL) Secures FDA Orphan Drug Status for LUMRYZ | AVDL Stock News - GuruFocus

Jun 05, 2025

Avadel Pharmaceuticals Receives FDA Orphan Drug Designation - TipRanks

Jun 05, 2025

Avadel Pharmaceuticals Receives Orphan Drug Designation From FDA For Lumryz - marketscreener.com

Jun 05, 2025

FDA grants orphan drug status to Avadel’s IH treatment - Investing.com Australia

Jun 05, 2025

FDA Orphan Drug Designation Gives LUMRYZ 7-Year Market Exclusivity for Sleep Disorder Breakthrough - Stock Titan

Jun 05, 2025

Jun 04, 2025

AVDL Stock Quote Price and Forecast - CNN

Jun 04, 2025

Jun 02, 2025

Nuveen Asset Management LLC Purchases 54,773 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World

Jun 02, 2025

May 31, 2025